Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus DEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus DEXACORT.
BETAMETHASONE SODIUM PHOSPHATE vs DEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to suppress inflammation, immune response, and reduce capillary permeability.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
0.5-9 mg/day IV or IM in divided doses every 12-24 hours; acute conditions may require 4-8 mg IV initially.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours (plasma); biological half-life (HPA axis suppression): 24-36 hours.
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Renal: 90-95% as inactive metabolites; biliary/fecal: <5%.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Category D/X
Category C
Corticosteroid
Corticosteroid